Ashton Thomas Private Wealth LLC Lowers Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Ashton Thomas Private Wealth LLC trimmed its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.4% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 43,632 shares of the biopharmaceutical company’s stock after selling 623 shares during the period. Ashton Thomas Private Wealth LLC’s holdings in Gilead Sciences were worth $3,196,000 as of its most recent filing with the SEC.

Other large investors have also recently made changes to their positions in the company. Altfest L J & Co. Inc. purchased a new stake in Gilead Sciences in the fourth quarter valued at approximately $210,000. Federated Hermes Inc. grew its stake in shares of Gilead Sciences by 4.9% in the fourth quarter. Federated Hermes Inc. now owns 3,787,355 shares of the biopharmaceutical company’s stock valued at $306,814,000 after buying an additional 175,925 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Gilead Sciences by 1.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 7,281,489 shares of the biopharmaceutical company’s stock valued at $589,873,000 after buying an additional 87,482 shares during the period. Wetzel Investment Advisors Inc. acquired a new position in Gilead Sciences in the 4th quarter valued at about $74,000. Finally, Eagle Asset Management Inc. boosted its stake in shares of Gilead Sciences by 23.6% in the fourth quarter. Eagle Asset Management Inc. now owns 317,539 shares of the biopharmaceutical company’s stock valued at $25,724,000 after purchasing an additional 60,697 shares during the period. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $68.63, for a total value of $137,260.00. Following the transaction, the insider now directly owns 96,380 shares in the company, valued at approximately $6,614,559.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.29% of the stock is owned by company insiders.

Gilead Sciences Stock Performance

Shares of NASDAQ GILD traded down $0.03 during trading hours on Friday, reaching $66.56. The stock had a trading volume of 981,054 shares, compared to its average volume of 7,532,693. The firm has a 50-day moving average of $66.06 and a 200-day moving average of $72.25. The firm has a market cap of $82.92 billion, a price-to-earnings ratio of 184.08, a PEG ratio of 2.83 and a beta of 0.18. The company has a current ratio of 1.08, a quick ratio of 0.94 and a debt-to-equity ratio of 1.31. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $87.86.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, beating the consensus estimate of ($1.49) by $0.17. The business had revenue of $6.69 billion during the quarter, compared to the consensus estimate of $6.36 billion. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. The company’s revenue was up 5.3% compared to the same quarter last year. During the same period in the prior year, the company earned $1.37 earnings per share. Equities research analysts predict that Gilead Sciences, Inc. will post 3.75 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, June 27th. Investors of record on Friday, June 14th were issued a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.63%. The ex-dividend date of this dividend was Friday, June 14th. Gilead Sciences’s dividend payout ratio is currently 855.56%.

Analysts Set New Price Targets

GILD has been the topic of a number of research reports. Robert W. Baird reiterated a “neutral” rating and set a $80.00 target price on shares of Gilead Sciences in a report on Thursday, June 20th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $74.00 target price on shares of Gilead Sciences in a report on Monday. HSBC raised Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price target on the stock in a research report on Wednesday, April 24th. Maxim Group cut their target price on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a research note on Wednesday, May 1st. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research note on Friday, April 26th. Twelve research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $83.47.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.